1. Home
  2. AACG vs KYNB Comparison

AACG vs KYNB Comparison

Compare AACG & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AACG

ATA Creativity Global

HOLD

Current Price

$1.00

Market Cap

31.0M

Sector

Real Estate

ML Signal

HOLD

KYNB

Kyntra Bio Inc. Common Stock

N/A

Current Price

$7.10

Market Cap

31.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AACG
KYNB
Founded
1999
1993
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.0M
31.9M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
AACG
KYNB
Price
$1.00
$7.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.5K
34.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$0.15
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$6.67
52 Week High
$2.58
$9.58

Technical Indicators

Market Signals
Indicator
AACG
KYNB
Relative Strength Index (RSI) 52.92 43.12
Support Level $0.76 $6.67
Resistance Level $1.08 $8.89
Average True Range (ATR) 0.05 0.38
MACD 0.00 0.06
Stochastic Oscillator 45.16 33.67

Price Performance

Historical Comparison
AACG
KYNB

About AACG ATA Creativity Global

ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.

About KYNB Kyntra Bio Inc. Common Stock

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

Share on Social Networks: